Vaxiion Therapeutics, LLC

Matthew J Giacalone

Gary H Ward

Michael James Newman

Stanley Maloy

Shingo Tsuji

Mark William Surber

Roger A Sabbadini

Neil Berkley

Disclosed herein are methods of terminally sterilizing bacterial minicells or compositions comprising bacterial minicells by exposure to ionizing irradiation. Also disclosed are terminally sterilized bacterial minicells, pharmaceutical compositions comprising the bacterial minicells, and methods of using the bacterial minicells and pharmaceutical compositions.

Ionizing irradiation sterilization of bacterial minicell-based biopharmaceuticals and methods of use

Disclosed herein are methods of terminally sterilizing bacterial minicells or compositions comprising bacterial minicells by exposure to ionizing irradiation. Also disclosed are terminally sterilized bacterial minicells, pharmaceutical compositions comprising the bacterial minicells, and methods of use the bacterial minicells and pharmaceutical compositions.

The present disclosure is related to immunomodulatory bacterial minicells and methods of using the minicells.

Immunomodulatory minicells and methods of use

Disclosed herein are compositions comprising immunomodulatory and oncolytic eubacterial minicells, and the use of the composition in immunomodulatory therapies for cancer. In some embodiments, the minicells are used in combination of immune checkpoint inhibitors in treating cancer.

Immunomodulatory and oncolytic minicells and methods of use

The present application relates to the use of bacterial minicells as targeted delivery agents in vivo and in vitro. Described herein are genetically engineered eubacterial minicells designed to preferentially target and deliver therapeutically relevant agents using a minicell surface coupling molecule capable of binding and displaying antibodies or other Fc-containing targeting moiety fusions and conjugates.

Therapeutic compositions and methods for antibody and Fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells

Embodiments of the present invention relates to the incorporation and use of a regulated genetic suicide mechanism for use in the improved purification of biologics, including adjunct use in various eubacterial minicell production and purification methodologies. Described herein are high-yield eubacterial minicell-producing strains with genetic modifications that comprise a regulated genetic suicide mechanism that irreparably destroys the parent cell chromosome such that live parental cells in a culture can be functionally eliminated at any time during the course of a minicell production and purification run. Embodiments of the present invention also describe methods useful in the elimination of live parental cells during the production of other cell-based biologics.

Regulated genetic suicide mechanism compositions and methods

The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.

Growing community of inventors

San Diego, CA, United States of America

Matthew J Giacalone